407 related articles for article (PubMed ID: 34043927)
1. Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics.
Saini KS; Punie K; Twelves C; Bortini S; de Azambuja E; Anderson S; Criscitiello C; Awada A; Loi S
Expert Opin Biol Ther; 2021 Jul; 21(7):945-962. PubMed ID: 34043927
[TBL] [Abstract][Full Text] [Related]
2. Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in advanced non-small cell lung cancer.
Salifu I; Singh N; Berraondo M; Remon J; Salifu S; Severson E; Quintana A; Peiró S; Ramkissoon S; Vidal L; Chico I; Saini KS
Cancer Treat Res Commun; 2023; 36():100713. PubMed ID: 37172552
[TBL] [Abstract][Full Text] [Related]
3. Antibody-drug conjugates in metastatic triple negative breast cancer: a spotlight on sacituzumab govitecan, ladiratuzumab vedotin, and trastuzumab deruxtecan.
McGuinness JE; Kalinsky K
Expert Opin Biol Ther; 2021 Jul; 21(7):903-913. PubMed ID: 33089726
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of Resistance to Antibody-Drug Conjugates.
Khoury R; Saleh K; Khalife N; Saleh M; Chahine C; Ibrahim R; Lecesne A
Int J Mol Sci; 2023 Jun; 24(11):. PubMed ID: 37298631
[TBL] [Abstract][Full Text] [Related]
5. Antibody-Drug Conjugates in Breast Cancer: a Comprehensive Review.
Pondé N; Aftimos P; Piccart M
Curr Treat Options Oncol; 2019 Apr; 20(5):37. PubMed ID: 30931493
[TBL] [Abstract][Full Text] [Related]
6. Next-generation antibody-drug conjugates for breast cancer: Moving beyond HER2 and TROP2.
Schlam I; Moges R; Morganti S; Tolaney SM; Tarantino P
Crit Rev Oncol Hematol; 2023 Oct; 190():104090. PubMed ID: 37562695
[TBL] [Abstract][Full Text] [Related]
7. Antibody-Drug Conjugates in Breast Cancer: Ascent to Destiny and Beyond-A 2023 Review.
Xiao T; Ali S; Mata DGMM; Lohmann AE; Blanchette PS
Curr Oncol; 2023 Jul; 30(7):6447-6461. PubMed ID: 37504334
[TBL] [Abstract][Full Text] [Related]
8. Antibody-drug conjugates in breast cancer: the chemotherapy of the future?
Nicolò E; Zagami P; Curigliano G
Curr Opin Oncol; 2020 Sep; 32(5):494-502. PubMed ID: 32657795
[TBL] [Abstract][Full Text] [Related]
9. Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy.
Goldenberg DM; Sharkey RM
Expert Opin Biol Ther; 2020 Aug; 20(8):871-885. PubMed ID: 32301634
[TBL] [Abstract][Full Text] [Related]
10. The Evolving Landscape of Immune Checkpoint Inhibitors and Antibody Drug Conjugates in the Treatment of Early-Stage Breast Cancer.
Bhardwaj PV; Abdou YG
Oncologist; 2023 Oct; 28(10):832-844. PubMed ID: 37597245
[TBL] [Abstract][Full Text] [Related]
11. TROP-2 directed antibody-drug conjugates (ADCs): The revolution of smart drug delivery in advanced non-small cell lung cancer (NSCLC).
Parisi C; Mahjoubi L; Gazzah A; Barlesi F
Cancer Treat Rev; 2023 Jul; 118():102572. PubMed ID: 37230055
[TBL] [Abstract][Full Text] [Related]
12. Antibody-Drug Conjugates for Breast Cancer.
Marmé F
Oncol Res Treat; 2022; 45(1-2):26-36. PubMed ID: 34915488
[TBL] [Abstract][Full Text] [Related]
13. Clinical Development of New Antibody-Drug Conjugates in Breast Cancer: To Infinity and Beyond.
Barroso-Sousa R; Tolaney SM
BioDrugs; 2021 Mar; 35(2):159-174. PubMed ID: 33666903
[TBL] [Abstract][Full Text] [Related]
14. Clinical development of antibody-drug conjugates in triple negative breast cancer: can we jump higher?
Zardavas D
Expert Opin Investig Drugs; 2022 Jun; 31(6):633-644. PubMed ID: 35451891
[TBL] [Abstract][Full Text] [Related]
15. Antibody-drug conjugates in lung and breast cancer: current evidence and future directions-a position statement from the ETOP IBCSG Partners Foundation.
Peters S; Loi S; André F; Chandarlapaty S; Felip E; Finn SP; Jänne PA; Kerr KM; Munzone E; Passaro A; Pérol M; Smit EF; Swanton C; Viale G; Stahel RA
Ann Oncol; 2024 Jul; 35(7):607-629. PubMed ID: 38648979
[TBL] [Abstract][Full Text] [Related]
16. Antibody-Drug Conjugates in Triple Negative Breast Cancer.
Keskinkilic M; Sacks R
Clin Breast Cancer; 2024 Apr; 24(3):163-174. PubMed ID: 38341370
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy in urothelial cancer: current status and future directions.
Piombino C; Tonni E; Oltrecolli M; Pirola M; Pipitone S; Baldessari C; Dominici M; Sabbatini R; Vitale MG
Expert Rev Anticancer Ther; 2023; 23(11):1141-1155. PubMed ID: 37772970
[TBL] [Abstract][Full Text] [Related]
18. Future potential targets of antibody-drug conjugates in breast cancer.
Corti C; Boscolo Bielo L; Schianca AC; Salimbeni BT; Criscitiello C; Curigliano G
Breast; 2023 Jun; 69():312-322. PubMed ID: 36996620
[TBL] [Abstract][Full Text] [Related]
19. Sacituzumab govitecan: an antibody-drug conjugate.
Sahota S; Vahdat LT
Expert Opin Biol Ther; 2017 Aug; 17(8):1027-1031. PubMed ID: 28503956
[TBL] [Abstract][Full Text] [Related]
20. Antibody-drug conjugates targeting Trop-2: Clinical developments in early breast cancer therapy.
Jeong JH; Kim SB
Breast; 2022 Dec; 66():199-203. PubMed ID: 36327625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]